Phase 3 trial in 241 adults with dermatomyositis: brepocitinib 30 mg improved Total Improvement Score at week 52 vs placebo (46.5 vs 31.2; difference 15.3), but 15 mg did not (37.5). Serious infections were more frequent with 30 mg (10% vs 1%).
RCTn = 241
Vleugels et al. A Phase 3 Trial of Brepocitinib in Dermatomyositis